Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2026)

Aquestive Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 16.25% year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $46.0 million, a 13.69% decrease from a year earlier, with the FY2025 full-year figure at $11.2 million, down 15.51% from the prior year.
• Non-Current Assets fell to $10.9 million in Q1 2026 per AQST's latest filing, from $11.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $17.6 million in Q1 2023 and bottomed at $10.9 million in Q1 2026.
• The 5-year median for Non-Current Assets is $13.6 million (2024), against an average of $14.2 million.
• Across the five-year window, Non-Current Assets jumped 34.37% in 2023 and slipped 21.21% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $17.2 million in 2022, then slipped by 4.25% to $16.5 million in 2023, then slipped by 19.74% to $13.2 million in 2024, then retreated by 15.51% to $11.2 million in 2025, then decreased by 1.92% to $10.9 million in 2026.
• Per Business Quant, the three latest AQST Non-Current Assets figures stand at $10.9 million (Q1 2026), $11.2 million (Q4 2025), and $11.9 million (Q3 2025).